Novartis | NVS - Loan Capital



Novartis reported $24.06B in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Amgen USD 53.76B 253M Jun/2025
AstraZeneca USD 25.99B 1.9B Jun/2025
Bausch Health Companies USD 20.86B 369M Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Canopy Growth CAD 289M 178.93M Jun/2025
Corcept Therapeutics USD 0 0 Mar/2025
Drreddys Laboratories INR 59.47M 3.74B Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
GlaxoSmithKline GBP 15.3B 1.17B Jun/2025
Glaxosmithkline GBP 15.3B 667M Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Merck USD 33.97B 484M Jun/2025
Novartis USD 24.06B 2.4B Jun/2025
Novartis USD 24.06B 1.13B Jun/2025
Pacira USD 378.1M 3.2M Jun/2025
Perrigo USD 3.62B 24.2M Jun/2025
Pfizer USD 57.5B 137M Jun/2025
Prestige Brands USD 1.01B 256K Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
Sanofi 13.2B 211M Jun/2025
Sanofi 14.72B 2.93B Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
Zoetis USD 5.23B 4M Jun/2025